Research library

B

grade

Mazdutide showed a significant reduction in body weight and improvements in liver stiffness in a patient with GSD IXc, but further studies are needed to validate these findings.

20.6% reduction in body weight from 85.0 to 67.5 kg after 4 months.

summary

A

grade

Mazdutide showed significant weight reduction in adults with obesity or overweight, with higher doses leading to greater effects compared to placebo.

-18.1% bodyweight change with 16 mg mazdutide at 32 weeks, n=51, p<0.0001.

summary

A

grade

Dual GLP-1/glucagon receptor agonists may lead to significant weight loss and metabolic improvements, but further long-term studies are necessary to confirm these effects.

-6.65 kg absolute body weight reduction, MD, moderate certainty.

summary

D

grade

Dual GLP-1/glucagon receptor agonists can lead to significant weight loss and metabolic improvements, but further research is needed to confirm long-term safety and effectiveness.

-6.65 kg absolute body weight reduction, MD, moderate certainty.

summary

D

grade

Not reported in abstract.

summary

C

grade

Lower external resistance in microbial fuel cells enhances electrochemical performance and mtrA expression, indicating a trade-off with biofilm accumulation.

Maximum power density of 130 mW m^-2 at 10 Ω.

summary

D

grade

Not reported in abstract.

summary

A

grade

Belzutifan plus lenvatinib showed a significant improvement in progression-free survival compared to cabozantinib, but overall survival did not reach statistical significance.

Median progression-free survival 14.8 months (95% CI 11.2-16.6) for belzutifan-lenvatinib vs 10.7 months (95% CI 9.2-11.1) for cabozantinib; HR 0.70, one-sided p<0.0001.

summary

C

grade

This study achieved a final β-caryophyllene titer of 35.4 g/L using engineered yeast, marking a significant advancement in microbial production methods.

Final β-caryophyllene titer of 35.4 g/L.

summary

B

grade

This case suggests that intravenous lipid emulsion may be considered as a rescue therapy in severe quetiapine overdose when conventional measures fail, but further evidence is needed to establish its efficacy.

Glasgow Coma Scale score improved to 14/15 within three hours.

summary

B

grade

Higher levels of homocysteine and cysteine are linked to worse outcomes in intracerebral hemorrhage patients, while lower methionine levels may be protective.

AUC = 0.819

summary

C

grade

This study presents a new software tool for MRI analysis of bone that shows strong correlations with established measures, but its clinical applicability remains untested.

Not reported in abstract.

summary

D

grade

Mazdutide shows promise in improving glycemic control and weight in adults with type 2 diabetes, but further research is needed to confirm these findings.

MD −1.53%; 95% CI −1.70 to −1.35 for HbA1c reduction compared to placebo.

summary

C

grade

The HGM + Multi(+) platform significantly reduced tumor volume and doubled median survival in animal models of glioblastoma, but further research is needed to confirm these findings in humans.

Tumor volume reduced to approximately 5% of controls.

summary

C

grade

VCAN and ESM1 may serve as biomarkers for glomerular injury in diabetic kidney disease, reflecting different patterns of endothelial dysfunction and matrix remodeling.

Not reported in abstract.

summary

A

grade

Mazdutide shows promise in reducing weight and improving cardiometabolic health in nondiabetic adults with obesity, but further research is needed to confirm these results.

Body weight reduced by –7.72 kg.

summary

D

grade

2025 marks a significant year in diabetes therapeutics with the approval of innovative drugs like mazdutide, but access disparities remain a critical challenge.

Mazdutide approved as the world’s first dual GLP-1/glucagon agonist in China.

summary

C

grade

Mazdutide shows potential in ameliorating NAFLD symptoms in preclinical models by improving lipid metabolism and reducing inflammation, but human studies are needed to confirm these findings.

Not reported in abstract.

summary

A

grade

Mazdutide shows promise for managing obesity, with dose-dependent benefits on weight and metabolic health, but gastrointestinal side effects are common.

Mazdutide 16 mg reduced waist circumference by −14.46 cm (95% CrI: −20.83 to −8.14).

summary

C

grade

This study presents a novel piezoelectric bio-adhesive that achieved full-thickness healing in rat models of gastrointestinal perforation within 15 days.

Full-thickness healing within 15 days.

summary

B

grade

Biologic-naïve patients achieved faster and deeper responses to bimekizumab compared to those with prior biologic exposure, suggesting it may be beneficial to use this treatment earlier.

PASI reduction was 85.5% vs. 62.5% at week 4, p<0.001.

summary

B

grade

School nurses recognize their influence on HPV vaccine uptake but face challenges that hinder their efforts, indicating a need for additional support.

summary

B

grade

In patients with small incidental saccular unruptured intracranial aneurysms and acute ischemic stroke, standard antithrombotic regimens do not appear to increase the risk of aneurysm rupture.

Aneurysm rupture occurred in two patients (1.0%) during a mean follow-up of 28.6 ± 18.4 months, n=197.

summary

C

grade

This study highlights the genetic complexity of ceftiofur resistance in swine-derived E. coli, with resistant subpopulations maintaining significant levels even without antibiotic pressure.

Approximately 43% stabilization of resistant subpopulations in EP70A and EP91A under ceftiofur-free conditions.

summary

C

grade

Combination therapy with ceftolozane-tazobactam and meropenem may suppress bacterial resistance more effectively than monotherapy in treating Pseudomonas aeruginosa infections.

Combination therapy resulted in bacterial counts ≥2 log10 CFU per mL lower than the best performing monotherapy.

summary